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Development of the bovine mammary gland is a complex process that is regulated
by several hormones, growth factors and transcription factors including but not limited to
growth hormone (GH), insulin-like growth factor (IGF)-I and T-box (Tbx)2 and 3. Tbx2
and Tbx3 are transcription factors required for mammary gland development in humans
and known to regulate cell cycle. In addition, there is recent evidence that GH increases
expression of Tbx3 in osteoblasts independent of IGF-I. Based on these findings, we
hypothesized GH and IGF-I will increase Tbx2 and Tbx3 expression in bovine mammary
epithelial cells (MEC), the cell responsible for milk production. To test our hypothesis,
MAC-T cells (MEC line) were treated with GH at 100 (GH100) or 500 (GH500) ng/mL
or IGF-I at 100 (IGF100) or 200 (IGF200) ng/mL for 24 and 48 hours. As determined by
real-time RT-PCR, we did not observe a change in Tbx3 expression in cells treated with
GH (P ≥ 0.74). However, both IGF-I treatments increased Tbx3 expression (P ≤ 0.03).
Surprisingly, expression of Tbx2 was not detectable in MEC cells; however it was
expressed in mammary fibroblast cells. In fibroblast cells treated with GH500 and
IGF200, we did observe a change in Tbx2 or Tbx3 expression (P ≥ 0.76). In conclusion,
IGF-I regulates Tbx3 expression in bovine MEC and Tbx2 and Tbx3 expression are cell
type specific.
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REVIEW OF LITERATURE
Introduction
Within the United States dairy industry, maintaining udder health and maximizing
efficiency of production is essential for a dairy operation to be profitable. In 2009, the
United States dairy industry generated $24.3 billion dollars in revenue from dairy sales
(USDA: NASS, 2009). However, with rising costs of feed, it is becoming increasingly
more expensive to produce milk. For example, between 2005 and 2007 there was a 110%
increase in corn prices and a 59% increase in alfalfa prices (USDA: NASS, 2010). When
feed prices increase significantly, it not only increases the cost of producing milk, but
also reduces the profit made by the producer. As a result, farmers need to alter their
management practices to maximize efficiency in an effort to maintain a profitable dairy
operation. Efficiency of production can be impacted in several ways, one of which is
animal health.
In 2006, 23% of all dairy cattle culled from herds suffered from either mastitis or
other mammary gland abnormalities. An additional 16.1% of animals culled were due to
poor production (USDA: APHIS, 2007). This demonstrates that poor udder health and
function is accounting for 40% of the animal losses within the dairy industry and
therefore is an issue within dairy production. In an effort to improve efficiency of
production and udder health, research has focused on key elements within the mammary
gland in order to better understand mammary gland function. The data obtained from
these studies can be used to improve udder health and milk production which in turn will
benefit the dairy industry. Specifically, our research focuses on understanding the
mechanisms involved in regulating mammary gland development and its response to key
1

hormones and growth factors. This literature review will focus on general mammary
gland anatomy, development and function, as well as, discuss how the function of the
mammary gland is regulated in response to specific hormones, growth factors, and
transcription factors.

Bovine Mammary Gland Anatomy
Understanding the structure of the gland is necessary not only in production
agriculture but in mammary research. The bovine mammary gland can be divided into
three segments: 1) The mammary fat pad, 2) The stroma, and 3) The parenchyma
(Tucker, 1987). Each segment of the mammary gland contributes to the overall function
of the gland which is to produce milk and its components (protein, fat and
carbohydrates).
The mammary fat pad is a large deposition of fat on the dorsal aspect of the
bovine mammary gland and infiltrates into the mammary stroma. The mammary fat pad
plays a role in the ductile branching that occurs in mammary development, especially
during embryonic stages (Watson and Khaled, 2008). The stroma of the mammary gland
contains the support elements and connective tissue that surrounds the parenchyma. The
stroma is comprised of several cell types (fibroblasts, adipocytes, and myoepithelial
cells), collagen, lymphatic vessels and a vascular system (Akers, 2002; Connor et al.,
2007). In addition to providing support for the parenchyma, stromal tissue facilitates the
paracrine actions of growth factors that are required for proper mammary development
(Akers, 2006; Flint and Knight, 1997). The functions and roles of these growth factors
will be discussed in more detail later in the review. While the mammary fat pad and
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stroma play both supportive and developmental roles within the mammary gland they are
not responsible for the production of milk.
The parenchyma is the portion of the mammary gland that is considered to be the
functional aspect of the gland as this region contains the mammary epithelial cells
(MEC). Mammary epithelial cells are responsible for producing milk which includes milk
proteins, carbohydrates and fats (Akers, 2002). As a result, MEC are the focus of the
majority of mammary gland research in cattle (De Vries et al., 2010). In the mammary
gland, there are two main types of epithelial cells; luminal and basal epithelial cells
(Watson and Khaled, 2008). The basal epithelium is comprised of the myoepithelial cells
which aid in milk ejection from the gland. The luminal epithelial cells are comprised of
two cell types: 1) ductile epithelial cells and 2) secretory epithelial cells (Watson and
Khaled, 2008). The secratory epithelial cells line the walls of the alveolus and are
responsible for milk production (Watson and Khaled, 2008). Each individual alveolus is
grouped into lobules which are comprised of many alveoli. These cells are the focus of
our research and the literature review will focus on growth and development of these
cells from this point forward.

Mammary Gland Growth and Development
Mammary development occurs during four stages in mammals: 1) embryonic, 2) pubertal
(pre and post), 3) pregnancy, and 4) lactation (Akers, 2002; Tucker, 1987; Platonova et
al., 2007). Within these stages, physiologic and anatomical changes will occur that are
specific to that phase of mammary development.

3

Embryonic Mammary Development
Mammary development in the bovine commences with the formation of the
mammary band which occurs at day 30 of embryonic development (Akers, 2002). The
formation of the mammary band originates from the ectoderm germ layer of the embryo.
This occurs with the aid of several transcription factors and cell signals that are present at
different points throughout embryonic mammary development (See Tbx2 and Tbx3 in
Mammary Gland Development). In the absence of these factors, mammary gland
formation will arrest or fail to occur. From the structure of the mammary band, the
mammary bud will form by day 40 of embryonic development in cattle (Akers, 2002).
Embryonic mammary development will continue and eventually cease once the
rudimentary gland has been established (Hens and Wysolmerski, 2005; Watson and
Khaled, 2008).

Pubertal Mammary Development
Mammary development that occurs during puberty is synonymous with ductile
development and branching as opposed to lobulo-alveolar development which does not
occur until pregnancy (Tucker, 1987). In regards to mammary tissue growth, the stromal
elements of the mammary gland grow prior to puberty. In addition to stromal tissue
growth, allometric growth of the duct system of the mammary gland occurs just prior to
the onset of puberty (Tucker, 1987). Mammary development during this stage is
facilitated through the production of ovarian steroid (i.e., estrogen) resulting from the
onset of ovarian development (See Hormones and Growth Factors section). Allometric
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growth of the gland will continue through the initial estrus cycles after which the
mammary gland will continue isometric growth until the animal becomes pregnant
(Tucker, 1987).

Gestational and Lactational Mammary Development
Mammary development during pregnancy is synonymous with the establishment
of the lobulo-alveolar system. In addition to the development of these mammary
structures, several other changes occur in the anatomy of the mammary gland at this
stage. Prior to pregnancy the stroma is the more predominate tissues in the mammary
gland. During pregnancy, mammary ducts will elongate and there will be an increase in
mammary cell proliferation and alveoli formation. As result, these alveoli will replace the
mammary fat pad and “rearrange” the stromal elements of the mammary gland resulting
in the parenchyma becoming the dominate tissue type (Tucker, 1987). This change in
tissue predominance is necessary for the mammary gland to prepare for lactation. As
observed during puberty, allometric growth of the mammary gland will occur. This trend
in growth will continue, resulting in a 25% increase in the mass of the parenchyma with
every month of gestation (Swanson and Poffenbarger, 1979; Tucker, 1987).
Within the mammary gland, proliferation of MEC is needed in order to maximize
milk production. Cellular proliferation can be increased during pregnancy and lactation
through the action of hormones and growth factors (i.e., IGF-I; see Hormones and
Growth Factors section). Mammary epithelial cell proliferation will eventually slow
which correlates with the stage of lactation when milk yield begins to decrease (Tucker,
1987).

5

Mammary Epithelial Cell Development
On the cellular level, MEC must also change cytologically in order to be capable
of milk production. Organelles within the cell, specifically the Golgi apparatus and the
endoplasmic reticulum, are responsible for the production of milk components. Therefore
these organelles must undergo significant changes during pregnancy and lactation. In
non-pregnant cattle, the Golgi apparatus and endoplasmic reticulum (ER) are
underdeveloped. This is in contrast to late gestation and lactation in which the ER will
produce milk proteins and fatty acids while the Golgi apparatus will synthesize lactose,
process casein proteins and package cellular products (Akers, 2002; Oka and Yoshimura,
1986; Mills and Topper, 1970). In order for these cytological changes to occur there must
be differentiation of MEC. Differentiation of the MEC requires the presence of several
hormones, two of which are glucocorticoids and prolactin. Glucocorticoids are needed to
develop the rough ER and prolactin is needed for the maturation of the Golgi apparatus as
well as the secretory vesicles (Akers, 2002; Mills and Topper, 1970). Once MEC have
proliferated and differentiated, with the aid of hormones and growth factors, the
mammary gland is then capable of lactation.

Regulation of Mammary Development
The development of the mammary gland is a complex process that consists of
many stages. Therefore, it is not surprising that there is a considerable amount of
regulation that occurs throughout mammary gland development. Key regulatory factors
of mammary development include 1) hormones, 2) growth factors, and 3) transcription
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factors. Understanding the roles of these regulatory mechanisms in MEC function allows
for a better understanding of the mammary gland. These regulatory factors will be the
focus of the remainder of this literature review.

Hormones and Growth Factors
Estrogen
The ovarian steroid, estrogen, aids in the growth of the mammary gland by
facilitating ductile system development and assisting in the establishment of the lobuloalveolar system during pregnancy (Connor et al., 2007). Like all hormones and growth
factors, receptors must be present on a specific tissue type in order for the action of the
hormone to be carried out. Within mammary tissue, estrogen receptors are present on the
ductile MEC, which coincides with the role of estrogen in ductile development (Capuco
et al., 2002). One of the ways that estrogen facilities ductile development within the
mammary gland is by increasing proliferation of MEC. This was observed in studies
where animals were treated with exogenous estrogen and an increase in ductile MEC was
observed (Woodward et al., 1993; Connor et al., 2007).
In addition, growth of the mammary gland in the absence of estrogen has been
evaluated through the use of overiectomized animals. In 2007, Connor et al, evaluated
mammary development in overiectomized heifers compared to a group of control
prepubertal heifers (Connor et al., 2007). It was observed that in overioectomized heifers
there is a decreased amount of epithelial cell proliferation in the mammary gland.
However within this study, mammary development was restored in ovariectomized
animals when exogenous estrogen was administered (Connor et al., 2007), thus
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demonstrating that estrogen is needed during prepubertal and pubertal mammary gland
development.

Prolactin
The hormone prolactin also plays a critical role during mammary development.
Secreted by the anterior lobe of the pituitary gland, prolactin is responsible for inducing
MEC differentiation (Riley et al., 2009). Prolactin regulates several transcription factors
(i.e., STAT-5 and ELF-5) during differentiation and facilitates the production of casein, a
major milk protein, in differentiated cells. Prolactin facilitates these changes by
interacting with specific cell signaling pathways (i.e., Jak2-Stat5: Riley et al., 2009)
which will be discussed in the transcription factor portion of this literature review.

Growth Hormone
Growth hormone has been demonstrated to have a positive effect on lactation in
cattle and is commonly used in commercial dairy operations to improve production.
Growth hormone, also known as bovine somatotropin (bST), increases milk yield in the
bovine by partitioning nutrients to the mammary gland for use in milk production
(Bauman, 1999). In regards to mammary development, studies in rodents have
determined that GH is needed for proper growth of mammary ducts during puberty and
the development of the lobulo-alveolar system during pregnancy (Kleinberg and Ruan,
2008).
Growth hormone can act on target tissues through two mechanisms: 1) indirect
action and 2) direct action. Within both mechanisms, GH is released from the anterior
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lobe of the pituitary gland in response to growth hormone releasing factor (GRF).
Alternately, GH release is inhibited through the actions of somatostatin (Roelfsema and
Clark, 2001; Renaville et al., 2002). When GH acts indirectly, GH will bind receptors
present on tissue (bone, adipose, and muscle, liver) and cause the production and release
of the somatomedian, IGF-I. Insulin-like growth factor-I will in turn carry out the actions
of GH on specific tissues. It is through GH binding to the liver and causing production of
IGF-I that GH acts indirectly on mammary tissue (Kleinberg and Ruan, 2008; Cohick,
1998). Growth hormone can also act directly on target tissues such as the bone, muscle,
and adipose (Le Roith et al., 2001; Govoni et al., 2006). In order for there to be direct
action of GH on a tissue, functional GH receptors (GHR) must be present (Le Roith et al.,
2001). Unlike the aforementioned tissues, it is questionable as to whether a functional
GHR is present within the mammary gland (Akers, 2002; Cohick, 1998).
Studies have demonstrated that GHR mRNA and receptor protein are present in
the bovine mammary gland (Plath and Gabler, 2001). In contrast, early experiments
which conducted ligand binding assays were not able to detect binding of GH to the GHR
of mammary tissue (Akers, 2002). It is hypothesized that GH is able to act directly on the
stromal elements of the mammary gland (Flint and Knight, 1997). Specifically, the
fibroblasts within the stroma are responsive to GH treatment (Flint and Knight, 1997). In
response to GH, fibroblast cells will produce IGF-I. This locally produced IGF-I will act
on the surrounding tissue in a paracrine action and it is believed that this IGF-I plays a
critical role in the mammary gland development (Baumrucker and Erondu, 2000; Flint
and Knight, 1997). This also suggests that the stroma of the mammary gland plays a role
beyond a structural support element.
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Insulin-Like Growth Factor-I
Insulin-like growth factor-I has been found to regulate cell cycle, increase
proliferation, and prevent apoptosis of MEC (Cohick, 1998). The mechanisms through
which IGF-I regulates cell cycle was evaluated in mice where treatment with IGF-I
increased several cyclin molecules, in particular cyclin D1 and cyclin E (Stull et al.,
2004). These molecules are needed within the G1 phase of the cell cycle. Within this
phase, the cell increases in size and prepares for the S phase, where DNA replication will
occur (Stull et al., 2004). A relationship has been found between the concentrations of
IGF-I in the blood of the animal and stage of mammary development. Specifically, IGF-I
concentrations increase during pregnancy and then decreases immediately following
parturition (Baumrucker and Erondu, 2000). However, as the lactation period advances
IGF-I concentrations in the blood will continue to increase (Baumrucker and Erondu,
2000). The increase in IGF-I concentrations during lactation could be a way through
which apoptosis of existing MEC is prevented, thus sustaining lactation for a prolonged
period of time.
The need for IGF-I for mammary development has been demonstrated in several
experiments. Studies using IGF-I knockout mice have demonstrated that animals
deficient in IGF-I lack proper mammary development which is not restored when treated
with GH (Kleinberg and Ruan, 2008). These results suggest that IGF-I may be mediating
the actions of GH on the mammary gland during development as well (Kleinberg and
Ruan, 2008).
In summary, hormones and growth factors are key regulators of the different
stages of mammary development. In particular, they facilitate growth of the different
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structural elements of the gland (ductile and lobuloaleveolar system) as well as the
development and differentiation of MEC. However there is also another subset of
regulatory elements that are needed throughout mammary gland development and are
directly involved in gene expression. These elements are transcription factors.

Transcription Factors
One of the ways in which hormones and growth factors can facilitate mammary
growth and development is through transcription factors. Three transcription factors are
needed during mammary development are GATA binding protein-3 (GATA-3), signal
transducer and activator of transcription-5 (STAT-5), and ets transcription factor-5 (ELF5) (Oakes et al., 2006; Siegal and Muller, 2010).

GATA-3
GATA-3 is a transcription factor that has been found to be involved in luminal
mammary cell type specification and maintains differentiated mammary epithelial cells
(Siegel and Muller, 2010). In mice, the use of a cre/lox system to conditionally disrupt
GATA-3 resulted in a knockdown of GATA-3 function in the mammary gland. In these
mice, the MEC lacked the ability to differentiate. As a result, these animals demonstrated
improper lobulo-alveolar development and did not lactate or produce milk proteins like
the wild type animals (Siegal and Muller, 2010). This demonstrates that GATA-3 is
necessary for differentiation of MEC and proper mammary development for lactation to
occur.
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Signal Transducer and Activator of Transcription-5 (STAT-5)
Another transcription factor that regulates mammary development is STAT-5.
Signal transducer and activator of transcription-5 expression is induced by prolactin and
is responsible for aiding in alveolar development, establishing cellular polarity, milk
protein production and cell-cell interactions (Oakes et al., 2006). By conditionally
knocking-down STAT5A and STAT5B gene expression, researchers observed a decrease
in MEC differentiation in pregnant animals and a failure of these animals to lactate
(Siegel and Muller, 2010). In STAT5 knockout animals there was also a decrease in the
number of luminal alveolar progenitor cells (Siegal and Muller, 2010). However, if
expression of this gene was restored, the mice resumed the normal mammary phenotype
(Siegal and Muller, 2010). This demonstrates the role of STAT-5 in establishing
differentiated mammary epithelial cells.

Ets Transcription Factor-5 (ELF-5)
Ets transcription factor-5, like GATA-3 and STAT5, is responsible for controlling
alveolar development. This transcription factor, like GATA-3, plays a role in switching
the mammary gland from a state of cellular proliferation to cellular differentiation during
pregnancy. Ets transcription factor-5 expression is induced by prolactin. This was
determined through the use of prolactin-receptor deficient mice (Oakes et al., 2006).
Similar to the other transcription factors, a knockdown of ELF-5 gene expression results
in failure of luminal mammary epithelial cells to differentiate (Siegal and Muller, 2010).
These aforementioned transcription factors are an example of some of the downstream
targets of hormones and growth factors that regulate mammary development. By altering
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the expression of these transcription factors regulation of mammary development is able
to occur.
T-Box Genes and the Mammary Gland
Transcription factors are not just present during lactation and pregnancy. The
establishment of the rudimentary mammary gland during embryonic mammary
development also relies on transcription factors. Two of these transcription factors are Tbox (Tbx) 2 and Tbx3. These transcription factors are examples of Tbx genes, which are
a family of transcription factors that were first discovered in 1927. Today, 18 Tbx genes
have been identified and can be categorized into five subfamilies (T, Tbx 1, 2, 6 and
Tbr1; Naiche et al., 2005). These genes are expressed in several different tissue types and
are critical during embryonic development when these transcription factors aid in the
establishment of germ layers and organs (Abrahmas et al., 2010).
All Tbx transcription factors contain a “T-box” DNA binding domain also known
as the Tbx binding element. The Tbx binding element is 180 amino acids in size and is
highly conserved between all members of the family (Naiche et al., 2005; Coll et al.,
2002). Both Tbx2 and Tbx3 contain this highly conserved domain however there are
differences within their structure. In contrast to other Tbx family members Tbx2 and
Tbx3 regulate development by binding DNA and repressing transcription (Rowley et al.,
2004). In order to do so, Tbx2 and Tbx3 contain specific structural domains, called
repressor domains. Tbx2 contains two repressor domains located near the N-terminal
domain (amino acids 1-53) and carboxy terminal domain (amino acids 529 -573) of the
protein (Abrahams et al., 2010). In contrast to Tbx2, Tbx3 contains only one repression
domain between amino acids 567 to 623 located near the carboxy terminal domain
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(Weiwei Fan et al., 2004). Despite variation in protein structure, the DNA sequence
encoding for the Tbx2 and Tbx3 transcription factors are 95% homologous to one another
(Coll et al., 2002). Consequently, these transcription factors are considered to be very
similar to one another in both form and function.
Tbx2 and Tbx3 are responsible for regulating the expression of many different
genes during embryonic and postnatal development. One of the genes that these
transcription factors regulate is the p19-Alternate Reading Frame (P19ARF), promoter
also known as p14-ARF in humans (Carlson et al., 2002; Platonova et al., 2007; Rowley
et al., 2004). This alternate reading frame is involved in the P19ARF-Mdm2-P53
pathway which is responsible for controlling cell cycle (Carlson et al., 2002; Platonova et
al., 2007; Rowley et al., 2004). When Tbx2 and Tbx3 represses transcription of the
p19ARF, there is an increase in cellular proliferation, inhibition of cellular senescence,
and a decrease in cellular apoptosis (Platonova et al., 2007).
By inhibiting cellular senescence, which is a state in which cellular growth is
arrested (Collado et al., 2007); Tbx2 and Tbx3 alter cellular growth. This is believed to
be one of the mechanisms through which Tbx2 and Tbx3 are involved in tumerogenisis
within the mammary gland (Rowley et al., 2004). The implications of what is known
about Tbx2 and Tbx3 in inhibiting senescence and how it translates to our research will
be discussed later in the rationale and hypothesis section.
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Role of Tbx3 and Tbx2 in the Mammary Gland
Embryonic Mammary Development
Tbx3 has been found to play a key role in the formation of the mammary placodes
from the mammary line. These placodes will eventually become the parenchyma of the
mammary gland. In mice, Tbx3 is expressed at day 10.5 gestation, which is typically the
time in which the mammary placodes are established. It is also thought that Tbx3 plays
an active role in the formation of the mammary gland from the cells of the ectoderm
(Hens and Wysolmeske, 2005). In humans, a haploinsufficency of Tbx3 is not lethal but
results in Ulnar Mammary Syndrome (UMS). This disorder is characterized by mammary
gland hypoplasia which further demonstrates the critical role of Tbx3 in mammary gland
development (Carlson et al., 2002; Platonova et al., 2007).
As stated previously, Tbx2 is a repressor much like Tbx3; however Tbx2 is not
expressed within the epithelial buds of the mammary gland. Instead, Tbx2 is expressed in
the mesenchyme of the developing embryonic mammary gland (Chapman et al., 1996).
Tbx2 and Tbx3 function independently of each other and Tbx2 has been found to play a
role in the regulation of adhesion molecules such as cadherins and integrans during
embryonic development (Abrahams et al., 2010; Chen et al., 2001). As a result, it has
been hypothesized that Tbx2 could play a role in the migration as well as invagination of
the cells when the mammary placodes are being formed (Hens and Wysolmeske, 2005).
Within our research we want to determine if Tbx2 is expressed within the stromal tissue
of the mammary gland of adult cattle and if its function is similar to Tbx3 within this
tissue type.
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Role of GH and IGF-I on Tbx gene expression
Within the mammary gland GH, IGF-I, and the transcription factors Tbx2 and
Tbx3 are important regulators of mammary gland development and function. However,
there is limited information on the interactions of these factors and their role in postnatal
mammary gland development and function. Recent research has demonstrated that GH
regulates Tbx3 gene expression in bone (Govoni et al., 2006). Within this study, GH
deficient lit/lit mice were treated with exogenous GH and gene expression of Tbx3 was
quantified (Govoni et al., 2006). In treated animals, Tbx3 expression significantly
increased within bone tissue. Similar results were observed in a MC3T3-E1 osteoblast
cell line when cells were treated with 100 ng/mL of GH. To determine if the increase in
Tbx3 gene expression was mediated directly by GH, cells were pre-treated with
IGFBP-4, a known inhibitor of IGF-I, and a similar increase in Tbx3 was observed.
These findings suggest that the increase in Tbx3 gene expression is mediated directly by
GH, independent of IGF-I (Govoni et al., 2006). Knowing that GH and IGF-I are needed
during mammary development and that GH alters Tbx3 expression in bone, one of the
objective of our research was to evaluate the effect of these growth factors on Tbx3 gene
expression within the mammary gland.
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RATIONALE AND HYPOTHESES
It is well established that hormones, growth factors, and transcription factors
regulate mammary gland development. Two of these transcription factors are Tbx2 and
Tbx3. Tbx2 and Tbx3 are expressed in the early stages of embryonic development and
are responsible for establishing the early structures of the mammary gland. Little is
known about the postnatal role, gene expression and regulation of Tbx2 and Tbx3 in the
mammary gland. The majority of what is known about these genes in postnatal mammary
development is often pertaining to cancer rather than their function in healthy mammary
tissue (Rowley et al., 2004). In regards to the bovine mammary gland, to our knowledge,
the role of these genes in bovine mammary development is not known and has yet to be
evaluated.
It is also well known that mammary development is regulated by two growth
factors, GH and IGF-I as previously discussed in the literature review. Recent research
also suggests that the somatotropic axis may regulate Tbx3 expression in other tissues.
Knowing that Tbx2 and Tbx3 are essential for mammary development and that GH and
IGF-I are involved in mammary development we developed the following hypotheses:
1) GH and IGF-I will increase Tbx3 expression in MEC.
2) GH and IGF-I will increase Tbx2 expression in MEC.
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MATERIALS AND METHODS

Mammary Tissue
Mammary tissue for RNA extraction was obtained from mammary parenchymal tissue
from lactating cattle at slaughter. Tissues were excised and snap frozen in liquid nitrogen
and stored at -80 ºC.

Cell Culture
MAC-T cells used in experiments were generously provided by W. Cohick
(Rutgers University) and M. Akers (Virginia Polytechnic Institute and State University).
Primary MEC were established using a protocol from Wellnitz and Kerr, 2004.
Mammary cells were obtained from lactating dairy cows at slaughter. Immediately
following slaughter, the mammary gland was removed from the animal and tissue was
aseptically removed from the mammary gland and transported back to lab on ice in
Hank’s Balanced Salt Solution (HBSS; Invitrogen, Carlsbad,CA), 5 µg/mL Fungizone
(Sigma-Aldrich, St. Louis, MO), 20 µg/mL Penicillin (Thermo Fischer Scientific,
Waltham, MA), 20 µg/mL Streptomycin (Thermo Fischer Scientific, Waltham, MA) ,
and 25 µg/mL Gentamycin (Sigma-Aldrich, St. Louis, MO). When culturing primary
MEC, culture contamination with fibroblasts was common. To remove this cell type
selective trypsinization was performed and the fibroblasts were cultured separately.
When subculturing cells, MEC were grown to 80% confluence in DMEM
(Invitrogen, Carlsbad,CA) supplemented with 10% FBS (Thermo Fischer Scientific,
Waltham, MA), 10 µg/ml Penicillin/Streptomycin, 0.1 µg/mL Fungizone, 25 µg/mL
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Gentamycin and 5 µg/mL Bovine Insulin (Sigma-Aldrich, St. Louis, MO). Cells were
incubated at 37º C/ 5% CO2. MACT cells and fibroblasts were cultured in the same
conditions as MEC.
For experiments, MAC-T and MEC were plated at a density of 100,000 cells/well
in Phenol Red Free (PRF) DMEM (Sigma-Aldrich, St. Louis, MO) supplemented with
10% FBS. When plating fibroblasts, 150,000 cells/well were plated. At 70% to 80%
confluence, all cells were serum deprived for 24 hours in PRF/Serum-Free DMEM
supplemented with 0.2% BSA (Sigma Aldrich, St. Louis, MO) and 30nM sodium selenite
(Sigma-Aldrich, St. Louis, MO). After serum depravation, cells were rinsed with PBS
and treated with either control media containing 0.02% BSA and 30 nM sodium selenite
(Sigma-Aldrich, St. Louis, MO) or control media plus 100 ng/mL of bovine GH, 500
ng/mL bovine GH, 100 ng/mL human IGF-I or 200 ng/mL human IGF-I (National
Hormone and Peptide Program, Torrance, CA) for 24h or 48h

RNA extraction
For cell cultures, media was removed from cells and cells were rinsed with PBS
prior to addition of 1mL TriReagent (Sigma-Aldrich, St. Louis, MO). For mammary
tissue, tissue was ground in a mortar cooled with liquid nitrogen prior to the addition of
TriReagent. RNA was extracted using a Qiagen Mini Kit according to the manufacturer`s
protocol (Qiagen, Valencia, CA). Genomic DNA was removed from samples through the
use of a DNA Free Kit (Ambion, Foster City, CA). Samples were diluted to a
concentration of 30 ng/µL using a Nanodrop spectrophotometer. Quality of RNA was
determined by using Experion analysis (BioRad, Hercules,CA).
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Reverse Transcription (RT) - PCR
RT-PCR was performed using 300 ng total RNA with OligoDT primer (Ambion) and
master mix containing 5.5 µL of 5x Buffer (Invitrogen, Carlsbad, CA), 1 µL dNTP
(Promega, Madison, WI), 2 µL DTT and 0.5 µL Superscript II (Invitrogen, Carlsbad,
CA) for a total reaction volume of 20 µL. The samples and master mix underwent a
standard reverse transcription protocol starting at 70 ºC for 10 min, 4ºC for 20 min, 37ºC
for 3 min, 42ºC for one hour, 4ºC for 3 min, 90ºC for 2.5 min. Resulting cDNA was then
diluted using 80 µL of Nuclease Free Water (Thermofisher Scientific, Waltham, MA)
and stored at -20ºC.

Real-time RT-PCR
Primers were designed using Primer3 and NCBI BLAST. DNA oligos were synthesized
by Integrated DNA Technologies (Coralville, IA; Table 1). The endogenous control
gene selected was ribosomal protein subunit (RPS) 15 (Bionaz and Loor, 2007).
Real-time RT-PCR was performed using Power SybrGreen Master Mix (Invitrogen,
Carlsbad, CA) and the ABI 7900 Fast Real-time PCR machine (Applied Biosystems,
Foster City, CA). The total volume of the reaction mixture was 25 µL containing 5 µL of
cDNA, 3 uL of nuclease free water, 1 µl each of 10 nM forward and reverse primer and
10µL of Sybergreen. For the Tbx3 master mix only 0.5µL of each forward and reverse
primer was used along with 4 µL of nuclease free water. PCR cycling conditions used
were a standard cycle with a starting stage of 50 ºC for 2 min and 95 ºC for 10 min. The
PCR entered the second stage at 95 ºC for 15 sec and 60 ºC for 1 min for 40 cycles. The
third and final stage consisted of 95 ºC for 15 sec and 60ºC for 15 sec with a 2% ramp to
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95 ºC for 5 min. ∆Ct values were obtained and these values were used to calculate the
∆∆

Ct values to determine changes in gene expression (Livak and Schittgen, 2001).

Changes in gene expression are expressed as fold changes from the control treatments.

PCR
PCR was used as a method to optimize primers and visualize gene expression. Primers
used were the same as those that were described in the real time RT-PCR portion of the
methods section. The total volume of the reaction mixture was 25 µL containing 5 µL of
cDNA, 5.5µL of nuclease free water, 12.5 µL of Go Taq Green Master Mix (Promega,
Madison, WI) and 1.0 µL of forward and reverse primers. PCR cycling conditions with a
starting stage at 95ºC for 3 min. The thermocycling parameters for the second stage were
94ºC for 30 sec, 60ºC for 1 min, 72ºC for 1 min repeating for 40 cycles concluding at
72ºC for 5 min. PCR products were then run in a 2% agarose gel and visualized using UV
light.

Statistical Analysis
Data were analyzed by ANOVA using SAS program (Version 2.9, SAS Institute Inc,
Cary, NC, USA). Data were evaluated by comparing control treated cells verses hormone
treated cells. The differences between the least square means of control vs. hormone
treated cells were used to determine P values. Statistical significance was considered at P
≤ 0.05
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RESULTS

IGF-I stimulates Tbx3 expression in bovine MEC
At both 24h and 48h time points we did not observe an effect of GH treatment on
Tbx3 gene expression (Figure 1; P ≥ 0.74). However, IGF-I at both doses increased Tbx3
expression significantly from controls (Figure 2; P ≤ 0.03) at 24h but not at 48h (Figure
2; P ≥ 0.17). To determine if IGF-I treatments were effective at both time points, IGFBP3
mRNA expression, which is known to increase in response to IGF-I, was determined in
treated and control cells. A significant increase in IGFBP3 mRNA was observed at both
time points for both doses (Figure 3; P ≤ 0.001), demonstrating that IGF-I treatment was
effective.

Tbx3, but not Tbx2, is expressed similarly in the mammary gland, fibroblasts and MEC.
To evaluate our second hypothesis we determined Tbx2 gene expression in MACT cells that were treated with either GH or IGF-I. We were unable to detect expression of
Tbx2 in the MAC-T cell line. To determine if this lack of expression was specific to the
MAC-T cell line, we isolated primary MEC and evaluated Tbx2 expression. Similarly,
Tbx2 expression was not detectable (Figure 4 and Figure 5). Based on our preliminary
findings that Tbx2 is expressed in mammary gland tissue (Figure 4 and Figure 5) and
previous findings that Tbx2 is highly expressed in lung fibroblasts (Teng et al., 2007), we
hypothesized that Tbx2 expression may be in mammary fibroblasts. Fibroblasts were then
isolated from the stroma of the mammary gland to detect Tbx2 expression. We observed
that Tbx2 is highly expressed in fibroblasts when compared to the mammary gland
(Figure 4 and 6 ; P = 0.01). To determine if Tbx3 was also differentially expressed we
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evaluated Tbx3 gene expression within the mammary gland and all cell types. We
determined that all cell types and mammary tissue expressed Tbx3 mRNA and gene
expression did not vary significantly from the expression in the mammary gland (Figure
6; P ≥ 0.14).

GH and IGF-I treatment did not alter Tbx2 and Tbx3 gene expression in fibroblasts
Based on our findings that Tbx2 expression in the bovine mammary gland was
primarily in fibroblasts, these cells were used as the model to determine the effect of GH
and IGF-I on Tbx2 gene expression. In addition, we wanted to determine if treatment
with GH or IGF-I would have an effect on Tbx3 expression in these cells. We did not
observe an effect of GH or IGF-I treatment on either Tbx2 or Tbx3 gene expression
(Figure 7; P ≥ 0.76). To determine if the cells were responsive to treatment, IGFBP3 gene
expression was evaluated. As expected, when cells were treated with IGF-I, IGFBP3
expression increased 63-fold from control fibroblasts cells (Figure 7; P value < 0.0001).
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FIGURE LEGENDS
Figure 1: GH treatment did not alter Tbx3 gene expression. All MAC-T cells were
cultured in control media (0.02% BSA) and treated with 100 ng/mL GH (GH100), 500
ng/mL GH (GH500) or without GH (control) for 24h or 48h. Data are presented as fold
change from the control and expressed as mean ± SE. No significant differences were
observed at P ≥ 0.74. GH = growth hormone, IGF-I = insulin-like growth factor-I, h=
hours, SE= standard error, BSA = bovine serum albumin.
Figure 2: IGF-I treatment increased Tbx3 expression. All MAC-T cells were cultured in
control media (0.02% BSA) and treated with 100 ng/mL IGF-I (IGF100), 200 ng/mL
IGF-I (IGF200) or without IGF-I (control) for 24h and 48h. Data are presented as fold
change from the control and expressed as a mean ± SE. * indicates P ≤ 0.03. IGF-I =
insulin-like growth factor-I, h= hours, SE= standard error, BSA = bovine serum albumin.
Figure 3: Treatment with IGF-I significantly increased IGFBP-3 expression in MAC-T
cells. IGFBP-3 expression was quantified for cells treated with 100 ng/mL IGF-I
(IGF100), 200 ng/mL IGF-I (IGF200) or without IGF-I (control) for 24h and 48h. Data
are presented as fold change from the control and expressed as a mean ± SE. * indicates
P ≤ 0.001. IGF-I = insulin-like growth factor-I, h= hours, SE= standard error, BSA =
bovine serum albumin, IGFBP3 = insulin-like growth factor binding protein-3.
Figure 4: Tbx2 expression is present in the mammary gland and fibroblasts. PCR
products from mammary gland tissue (MG), MAC-T cells, MEC cells, and fibroblasts
were run in an 2% agarose gel at 130 V. Bands were visualized using UV light.
RSP15 = Ribosomal protein subunit 15, MG = mammary gland, MEC= mammary
epithelial cells, UV = ultraviolet, PCR = polymerase chain reaction.
Figure 5: Tbx2 mRNA is expressed in fibroblasts in the bovine mammary gland. Data
are presented as fold change from the control and expressed as a mean ± SE. * indicates P
≤ 0.02. ND = Not detectable, MEC = mammary epithelial cells, MG = mammary gland.
Figure 6: Tbx3 is expressed similarly in all cell types in the bovine mammary gland.
Data are presented as fold change from the MG and expressed as a mean ± SE. A
significant different was not observed at P ≥ 0.13. MEC = mammary epithelial cells,
MG = mammary gland.
Figure 7: GH and IGF-I treatment did not alter Tbx2 or Tbx3 expression in fibroblasts.
Fibroblast cells were cultured in control media (0.02% BSA) and treated with 500 ng/ml
GH (GH500), 200 ng/mL IGF-I (IGF200) or without growth factors (control) for 24h.
Data are presented as fold change from the control and expressed as a mean ± SE.
* indicates P ≤ 0.0001. GH = growth hormone, IGF-I = insulin-like growth factor-I, SE =
standard error, IGFBP-3 = insulin-like growth factor binding protein-3.
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TABLES
Table 1: Bovine Specific Primers
Gene
RPS15
RPS15
Tbx3
Tbx3
Tbx2
Tbx2
IGFBP-3
IGFBP-3

Primer

Amplicon
length (bp)

Sequence (5’ to 3’)

Forward
Reverse

151
151
101
101
124
124
231
231

GCA GCT TAT GAG CAA GGT CGT
GCT CAT CAG CAG ATA GCG CTT
ATC GCT GTG ACT GCA TAC CA
TCT CTC CTG CCA TTT CCA GT
CTT GCA GTG CTC CTC CTA
CAC GCA GCT TAA GAT CGA CA
CAG AGC ACA GAC ACC CAG AA
TGC CCC CTA CTT ATC CAC ACA

Forward
Reverse
Forward
Reverse
Forward
Reverse

Primers were designed using Primer3 and NCBI Blast
RPS15 = ribosomal protein subunit-15, Tbx2 = T-box 2, Tbx3 =T-box 3,
IGFBP-3 = Insulin-like binding protein-3
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DISCUSSION
Tbx2 and Tbx3 expression in the bovine mammary gland
There is a limited amount of information about Tbx2 and Tbx3 gene expression in
adult mammary tissue. Consequently, the regulatory mechanisms, expression patterns,
and roles of these genes in postnatal mammary development are not known. Within our
research, we observed that there is differential expression patterns and regulation of Tbx2
and Tbx3 within the bovine mammary gland. We determined that Tbx2 expression is
localized within mammary fibroblasts whereas we were unable to detected expression in
MEC. Our observations of Tbx2 expression in fibroblasts are in agreement with data
from a study conducted by Teng et al in 2007. Within this study researchers observed
endogenous Tbx2 expression in the WI-38 fetal lung fibroblast cell line (Teng et al.,
2007). Other studies have evaluated Tbx2 expression in fibroblasts. However these
fibroblasts did not express Tbx2 endogenously and were transfected with a plasmid
containing a Tbx2 gene construct (Teng et al., 2007; Chen et al., 2001). In adult human
tissues it is known that heart, kidney, lung, mammary and ovarian tissue express Tbx2
(Law et al., 1995). However differential gene expression of Tbx2 and Tbx3 has yet to be
evaluated within these tissue types. Further research is needed to evaluate the expression
patterns within these tissues.
The expression pattern of Tbx2 in the fibroblasts in adult mammary tissue is
similar to what is observed in the embryonic mammary gland. Tbx2, but not Tbx3, is
expressed within the mammary mesenchyme which will later become the stroma
(Chapman et al., 1996). This conserved expression pattern suggests that it may be
necessary for postnatal mammary gland development and therefore must be maintained.
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In embryonic development, Tbx3 but not Tbx2 is expressed within the mammary
placodes which will later become the parenchyma (Chapman et al., 1996). Interestingly,
within our experiments we did observe that all cell types evaluated express Tbx3 similar
to one another. This suggests that Tbx3 expression within the fibroblasts may be
necessary postnatally however expression is prevented during the embryonic stages.
Overall, a potential reason for this differential gene expression between mammary
fibroblasts and MEC could be the need for tissue predominance to change throughout
mammary gland development.
As the mammary gland matures and transitions through puberty, pregnancy and
lactation, the predominate tissue type will change. There are several examples of
regulatory factors within the bovine mammary gland that will increase or decrease based
on the stage of mammary gland development and effect mammary tissue predominance.
An example of one of these factors is the transforming growth factor-β1 (TGFβ1: Akers,
2002; Plaut et al., 2003; Plath et al., 1997). This growth factor has been found to alter the
predominance of the mammary stroma and parenchyma especially as the gland prepares
for lactation to cease during involution. Transforming growth factor-β1 does this by
facilitating an increase in stromal cell proliferation, ECM break down, and MEC
apoptosis (Akers, 2002; Plaut et al, 2003; Plath et al., 1997). Transforming growth factorβ1 concentrations within the mammary gland will remain low throughout pregnancy and
lactation. However, as the gland prepares for involution TGFβ1 concentration will
increase significantly (Akers, 2002; Plath et al., 1997).
The temporal variation in TGFβ1 concentration is in direct correlation with the
stages at which a greater number of MEC are needed. This regulatory mechanism not
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only demonstrates that tissue remodeling occurs frequently within the mammary gland
but that Tbx2 and Tbx3 could be facilitating a similar role with the gland. Studies have
evaluated the effects of over expressing Tbx2 in the embryonic fibroblast cell line,
NIH3T3 (Chen et al., 2001). The results from this study suggest that Tbx2 reduces
collagen gene expression as well as cell adhesion molecules such as cadherins (Chen et
al., 2001). Within the mammary gland, collagen comprises the ECM of the stroma and is
produced by the fibroblasts. Without the ECM, MEC cannot differentiate properly and
therefore are not able to produce milk proteins. It is possible that Tbx2 may play a role in
regulating collagen production of mammary fibroblasts and therefore may affect MEC as
the gland transitions from one state to another. It is known that Tbx3 increases cellular
proliferation however it has also been determined that Tbx3 gene expression prevents
differentiation. Therefore further research needs to be conducted in MEC and fibroblasts
to determine how Tbx2 and Tbx3 expression changes during differentiation.
Within our research, we also observed differential regulation of the Tbx genes
within the mammary gland. In MAC-T cells, IGF-I increased Tbx3 gene expression.
However, in mammary fibroblasts, both Tbx2 and Tbx3 expression remained unaltered in
the presence of GH and IGF-I treatment. This suggests that IGF-I affects Tbx3 in MEC
and potentially does not affect Tbx2 or Tbx3 expression in fibroblasts of the stroma.
Therefore, this could be a mechanism through which proliferation of the MEC increases
differently from the stroma of the gland. It is believed that Tbx2 and Tbx3 are expressed
and function similar to one another (Coll et al., 2002). However, our findings suggest that
there is differential expression as well as differential regulation of expression of Tbx2
and Tbx3 in the bovine mammary gland. Further studies are need to evaluate Tbx2 and
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Tbx3 expression during the different stages of development in order to determine how
Tbx2 and Tbx3 expression changes within the parenchyma as well as the stroma over
time

Regulation of Tbx2 and Tbx3 by the Somatotropic Axis
In order for Tbx2 and Tbx3 to facilitate cellular proliferation and inhibit
senescence, the genes for these transcription factors must be transcribed. However, in an
effort to prevent uncontrolled cellular proliferation to allow for cellular senescence, the
expression of these genes is tightly regulated. Within embryonic development it has been
determined that Tbx2 and Tbx3 expression is regulated by a several signaling molecules
in many different tissue types (i.e., BMP, Shh: Trumpel et al., 2002). However, the
mechanisms for regulating Tbx2 and Tbx3 expression in the adult bovine mammary
gland have yet to be determined. Within our research, we observed that IGF-I increased
Tbx3 gene expression within MAC-T cells. This suggests Tbx3 may be a key mediator of
IGF-I action within the mammary gland. Further research is needed to determine if IGF-I
is directly mediating the increase of Tbx3 expression within the gland or if there are other
regulatory mechanisms involved in this process.
Our observations are in contrast to what was found in a study by Govoni et al., in
2006 where GH treatment increased Tbx3 gene expression independent of IGF-I (Govoni
et al., 2006). Within our cells, GH did not have an effect on Tbx3 gene expression. The
difference in findings between our work and the previous study could be due, in part, to
variation in the receptors present on these two tissue types and as a result the response of
the tissues to GH and IGF-I. It is well established that GHR are present on the germinal
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portion of bone (Le Roith et al., 2001; Hadley and Levine, 2007). However the presence
of a functional GHR in the MEC is debatable (see Hormones section of literature review).
Therefore, it is not clear if GH does not alter Tbx3 expression in MEC or if GH cannot
have an effect on these cells due to a lack of a functional GHR.
When fibroblast cells were treated with either GH or IGF-I we did not observed a
change in Tbx2 and Tbx3. It is known that GHR are present on fibroblasts and that these
cells also produce paracrine IGF-I which in turn can act on MEC. However, our results
suggest that within the mammary fibroblast cells of lactating animals there is no effect of
the somatotropic axis on Tbx3 and Tbx2 expression. Further studies are needed to
determine if this remains the same throughout the different stages of mammary
development. While IGF-I effects Tbx3 gene expression in MEC there may be other
growth factors or hormones that are needed in order to facilitate an increase in Tbx2 or
Tbx3 gene expression within mammary fibroblasts

Role of Tbx3 in mediating the Somatotropic Axis
Within the mammary gland one of the mechanisms through which mammary
growth occurs is through cellular proliferation induced by IGF-I (Akers., 2002; Cohick.,
1998). IGF-I increases cellular proliferation by activating several cell signaling cascades
that result in alterations of the cell cycle. Some of these pathways that are activated are
the ras/raf/mapk pathway and β-catenin which in turn will activate cyclin D1 and c-myc
(Akers, 2002; Hadsell et al., 2002). In a study conducted by Carlson et al., mammary
fibroblast cells were transfected with plasmids that would cause over expression of Tbx3,
H-Ras, and Myc (Carlson et al., 2002). When Tbx3 was over expressed in combination
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with H-Ras and/or Myc there was an increase in the immortalization of the cells (Carlson
et al., 2002). These results suggests that Tbx3 was working in cooperation with Myc and
H-Ras by down regulating the p19ARF resulting in cellular immortalization of MEF
(Carlson et al., 2002). As stated previously, IGF-I activates several cell signaling
cascades of which myc and ras belong to. Therefore, it is possible that by repressing
P19ARF that Tbx3 facilitates the actions of IGF-I resulting in an increase in cellular
proliferation of MEC. Further research is needed within this area to identify the
downstream targets of Tbx3 when MEC are treated with IGF-I.
In summary, we know that Tbx2 and Tbx3 are needed during embryonic
mammary development. Within our data, we observed that these transcription factors are
expressed in the adult mammary gland and the differential expression pattern observed
during embryogenesis is maintained into adulthood. We also observed in MEC that IGF-I
increases Tbx3 gene expression within these cells. However we did not observed an
effect of GH treatment on Tbx3 expression in MEC. This suggests that Tbx3 may
mediate the actions of IGF-I on the mammary gland and that the effects of GH treatment
on Tbx3 gene expression may be tissue type specific. Alternately, we did not observe an
effect of GH or IGF-I treatment on Tbx2 or Tbx3 expression in mammary fibroblasts.
Further research is needed to evaluate growth factors and hormones that may be involved
in modulating this genes expression in this cell type. In future research, Tbx2 and Tbx3
expression needs to be evaluated at the different stages of mammary development
especially during differentiation. We observed that Tbx3 may be mediating the actions of
IGF-I on MEC, but further research is needed to identify the downstream targets of Tbx3
within the bovine mammary gland.

38

APPENDICES

Appendix 1: Protocol for excising tissue from the bovine mammary gland
1. Set up the area that you will be using as a work surface. This entails washing
down the counters with a 1:10 bleach solution following up by wiping the surface
down with 70% Ethanol. Place white lab bench top covering over the work
surface.
2. Set up you tools that will be utilized to excise the tissue. Keep autoclaved scissors
and tweezers in tin foil until they are ready to be used. Affix scalpel blade to the
scalpel holder. Leave the blade covered by the protective foil wrapper so the
sterility is maintained.
3. Once the udder has been presented to you, prepare the udder for tissue excision.
Observe the udder for any signs of abnormalities (i.e.: slack quarter ect). Avoid
any regions that appear to be damaged due to mastitis. If there are any gross
abnormalities with the gland obtain samples from another gland.
4. Wash a portion of the gland with 70% Ethanol, taking care to clean the udder to
remove any debris. Make and incisions with the scalpel. Remove adipose tissue
and connective tissue using forceps
5.

Utilize alcohol to clean instruments, changing for new sterile ones if necessary.
Take care not to damage the tissue with the Ethanol. Excise the parenchymal
tissue as carefully and cleanly as possible. Large vessels, mammary fat pad, and
other undesired tissue should be avoided however this can always be removed
prior to mincing once back at the lab

6. Once the tissue has been excised, carefully place the tissue in a falcon tube
containing 35 mL of HBSS containing Penn/Step, Fungizone, Glucose and
Gentamycin that has been kept on ice. Do not leave at room temperature as this
can decrease the efficacy of the antibiotics.
7. Transport the tissue in media on ice back to the lab where it will be prepped for
isolation
•

Take tissue samples from the different quarters of the mammary gland ensuring
that you clean each surface well before making an incision. By doing this you are
not only getting tissue from different portions of the mammary gland but checking
the udder for any signs of mastitis or other abnormalities that could impact the
success of the isolation.

•

If collecting from more than one animal ensure that all tubes are labeled properly
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Appendix 2: Protocol for the isolation of bovine mammary epithelial cells
1. Clean the outside of the falcon tubes clean them with 70% Ethanol so as not to
introduce any contaminates to the hood.
2. Take fresh flacon tubes and add 35 mL HBSS . Aspirate off the HBSS that you
transported the tissue in and remove the tissue from the transport tube and place it
in the new tube. Swirl tissue around and then remove this HBSS. This is done to
rinse the tissue prior to mincing in an attempt to remove any foreign matter and
detritus
3. Mince tissue in flacon tube using a pair of scissors. Change scissors in between
tubes so as to prevent contamination. Rinse tissue frequently with HBSS to
remove milk as well as blood. Use transfer pipettes as it is easier than using the
vacuum. Mince until the tissue is approximately 1-5 mm3 in size.
4. Once tissue has been minced and cleaned it will be added to the digesting
mixture. The digesting mixture should contain the following: 250 mL of HBSS,
.5 mg/mL collagenase IV, .4 mg/mL Dnase I, .5 mg/ml hyaluronidase, 50 ug/mL
Gentamycin, and 2.5 ug/mL fungi zone. The digesting mixture should be
STERILE FILTERED prior to use. In the hood add the digesting mixture to an
AUTOCLAVED Erlenmeyer flask with a spinner bar. Allow the tissue to remain
in this mixture for three hours
5. Upon completing of the incubation utilize a large metal strainer to remove large
pieces of undigested tissue as well as fat. Place the resulting liquid into falcon
tubes and centrifuge at 40 G (rcf) for 5 min.
6. Resuspend in fresh HBSS and filter again through a smaller metal filter. Place the
resulting liquid into falcon tubes and centrifuge at 40 G (rcf) for 5 min. Remove
HBSS and resuspend in fresh HBSS and filter through a cell strainer (100 um).
Centrifuge at 40 G (rcf) for 5 min.
7. Resuspend the cell pellet in culture media. If there appears to be still some debris
use the cell strainer again but do not re-centrifuge. Plate out the cells and allow
them to incubate for 30 min at 37 degrees Celsius/5% CO
8. After 30 minutes gently decant off the media. The cells left behind should be
fibroblasts

9. Watch cells very carefully for ANY signs of contamination. Also watch for
fibroblast growth and use the “Removing Fibroblast Protocol” to prevent
overgrowth of the culture with fibroblasts.
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Appendix 3: Standard and PRF Dulbecco’s Modified Eagle Medium Preparation
To Prepare 1X Liquid Medium
1. Measure out 5% less distilled water than desired total volume of medium,
using a mixing container that is as close to the final volume as possible
2. Add powdered medium to 15 to 30°C (room temperature) water with
gentle stirring (DO NOT heat water)
3. Rinse out inside of package to remove all traces of powder
4. Add 3.7 g of Sodium Bicarbonate per liter of medium
5. Dilute to a desired volume with water. Stir until dissolved taking care not
to over-mix
6. Adjust pH of medium to 0.2-0.3 below desired final working pH. Use of
1N Sodium Hydroxide or 1N Hydrochloric Acid is recommended. After pH
has been adjusted, keep container closed until media is filtered
7. Sterilize immediately by membrane filtration
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Appendix 4: MAC-T/MEC/Fibroblast cell subculture
1. Bottles of media, PBS, and 50% Trypsin-EDTA/50% PBS should be warmed
prior to usage. Care should be taken so that the media does not stay in the water
bath for prolonged periods of time. Trypsin should never be placed directly in the
water bath.
2. Clean work area prior to usage with 70% Ethanol. Clean bottles from the water
bath with 70% Ethanol prior to inserting them into the hood.
3. Remove media from the plates using vacuum aspiration. Take care so as not to
damage or disturbed the cells
4. Add 2-3mL of warmed PBS to each plate. Do not add directly to the cells as this
could dislodge them. Gently swirl PBS on the plate so as to remove any
remaining media. Aspirate off PBS prior to addition of Trypsin-EDTA/PBS
solution.
5. Add 2-3 mL of Trypsin-EDTA/PBS to each plate. Place plates in incubator.
a. For MAC-T: Allow cells to incubate in the presence of TrypsinEDTA/PBS for 7-10 min
b. For MEC: Allow cells to incubate in the presence of Trypsin-EDTA/PBS
for 25 min
c. Fibroblasts: Allow cells to incubate in the presence of Trypsin-EDTA/PBS
for 6 min
6. Check plates at the end of trypsinzation to ensure that all cells have lifted then add
media to stop the action of the enzyme. Using a cell scraper is sometimes needed
for these cells. Be gentle when using the cell scraper so as to prevent cellular
damage and cell clumping.
7. Add contents of the plate to a 50 mL falcon tube and centrifuge to form a cell
pellet
a. For MAC-T and MEC: 600 rpm for 6.5 min
b. For Fibroblasts: 1400rpm for 4.5 min
8. After centrifugation, aspirate off media and resuspend cells in fresh media. The
amount of media added to the pellet will depend on the purpose for these cells. If
subculturing pass add 10 mL of media for every plate passed.
9. Plate cells and return them to the incubator. Cells will have to be subcultured
again once they reach 70%-80% confluence
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Appendix 5: Removal of Fibroblasts from Primary Bovine Mammary Epithelial
Cell Culture
HBSS Removal Technique
1. Remove media from the primary BMEC and rinse gently with warm PBS several
times.
2. Add HBSS solution containing .5 ug/mL fungizone,100,000 U/mL Penn/Strep,
and Gentamycin.
3. Allow cells to incubate in the presence of HBSS for 3hrs at 37 degrees
Celsius/5% CO2.
4. Remove HBSS and wash again several times with PBS. Wash slightly vigorously
so as to remove fibroblasts that may have changed morphology but not lifted.
5. Add fresh media to the plate and return to the incubator
Selective Trypsinization
1. Add 2 mL of 25% Trypsin-EDTA/75% PBS
2. Allow cells to incubate in the presence of trypsin for 3 min
3. Remove cells from the incubator and examine the plate. Look to ensure that the
fibroblasts have lifted and NOT the mammary cells
4. Remove the trypsin and fibroblasts and rinse with PBS. Use some force when
rising but do not be too vigorous as this will cause the mammary cells to detach.
5. Add 2 mL of 25% Trypsin-EDTA/75% PBS to the plate
6. Allow cells to incubate in the presence of trypsin for 10-12 min. Monitor the cells
periodically throughout this incubation. Once the cells have changed morphology
add media to deactivate the trypsin.
7. Remove cells from plate and place media and cells in centrifuge. Spin cells at 600
rpm for 6 min
8. Resuspend cells and plate out onto new plates containing on 5 mL of media per a
plate. Allow the plates to incubate for half an hour. This is to remove any residual
fibroblasts that may have remained after the first trypsinization.
9. Decant off the media ensuring not to disturbed the fibroblasts that have adhered to
the plate. Plate out decanted cells (performing a cells count at this point if need
be) in culture media and allow to grow until confluence.
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Appendix 6: RNA extraction
1. Rinse experimental plates with PBS and remove. Then add 1 ml TRI Reagent
(Sigma Aldrich, at no. T9424) to each well and scrape well with pipette tip so as
to remove the cells. Transfer the contents of the well to a 1.5 mL eppendoff tube.
2. Vortex the TRI Reagent mixture to homogenize. Allow the tubes to incubate for 5
min if extracting RNA immediately. If not, tubes should be stored in the freezer at
-80 °C.
3. Add 200 uL chloroform to each tube. Mix by inverting 5 -7 times and allow for it
to incubate at room temperature for 2-3 min. *Centrifuge these tubes at 12000 x g
for 15 min

4. Transfer the aqueous phase into a new eppendorf tube taking care not to disturb
the other layers. The total volume transferred will be close to 500 µL. Next Add
one volume (500 uL) of 70% EtOH to each tube and vortex
5. Transfer 700 uL of the sample into the RNA east Spin Column and centrifuge
8,000 X , 30s. Discard the resulting flow through and add 700 µL RWI wash
buffer. Take care to avoid adding any liquid directly onto the filter as this could
cause a decrease in RNA yield. Centrifuge spin column again at 8,000 X g 30s
6. Discard the flow through and collection tube put the filer on the new collection
tube. Add 500 uL of Buffer RPE to spin column ensuring that 100% Ethanol has
been added to the buffer prior to use. Centrifuge 8,000 x g, 30s and discard the
flow through.
7. Add 500 uL of Buffer RPE and centrifuge at 8,000 X g for 2 min. Discard the
flow through and centrifuge at 8,000 X g 1 min. Discard the flow through and
collection tube, put the filter on the new collection capped tube
8. Add 50uL of Rnase free water to the spin column and centrifuge at 8,000 X g for
1 min. Take 35-40 uL from the collection tube and put back on the filter
centrifuge at 8000 X g, 1 min
9. Collect the eluted RNA, in the capped collection tube, keep on ice, and spec it in
the Nanodrop. Aliquot it and store in the -80 freezer
•

When extracting RNA from fibroblasts centrifuge for 15 min at 4°C
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Appendix 7: Turbo DNA-Free Protocol
1. Thaw the reagents (10x Turbo DNase Buffer, Turbo DNase, DNase inactivation
reagent) on ice.
2. Add 0.1 volume of 10x turbo Dnase Buffer (i.e.: 5 uL of 50 uL RNA sample) and
1 uL Turbo Dnase to the RNA sample and mix gently. This is for routine DNase
treatment with RNA concentration of 10ug/50uL of sample. If it is more than this
con. Dilute your sample to have 10 ug/50 uL using C1V1=C2V2
3. Incubate at 37 °C for 20-30 min

4. Vortex the Dnase Inactivation reagent well as this mixture is very turbid. If
performing DNA-Free treatment on a significant number of samples be sure to
vortex frequently to prevent settling. Add 0.1 volume of resuspended DNase
Inactivation reagent.
5. Incubate for 5 min at room temp while mixing occasionally by flicking or tapping
6. Centrifuge at 10000 x g for 1.5 min
7. Transfer the supernatant to a fresh tube Note: Avoid disturbing the pellet
8. The final DNA-free RNA con. Is determined by Nano drop 1000.
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Appendix 8: Reverse Transcriptase PCR
1. Thaw the reagents on ice( Ambion OligoDT, Invitrogen Superscript kit II
containing DTT, 5X buffer and reverse transcriptase)
2. Add 1uL of OligoDT to each 10uL of normalized RNA sample (300ng/10ul) in 8
tube strips. This makes it a total of 11uL.NOTE: Always include a positive and
negative control
3. Place these tubes into the thermocycler and state the desired RT PCR program
(see below) and start step 1, 70˚C for 10min
70˚C for 10min
4˚C for 20min
37˚C for 3min
42˚C for 1hr
4 ˚C for 3min
90˚C for 2.30 min
10˚C forever
4. During the time of step 1, make the master mix. Do not add superscript until you
are ready to add the master mix to the samples.
Master Mix
5X Buffer5.5uL
dNTP1uL
DTT2uL
SuperscriptII 0.5 uL
(Reverse transcriptase)
NOTE: The above calculations are per sample, multiply it by the no. of
samples+2 for pipetting errors.
5. Pause the thermocycler when the temperature is dropping to 4˚C for the next step
(step 2). Take the samples with RNA and Oligo DT out of the machine and keep
it on ice.
6. Add SSII to the master mix, mix gently. Add 9uL of master mix to each sample ,
making it a total of 20uL ensuring that samples are kept on ice while adding the
master mix. Mix contents of tube with master mix by pippetting up and down
several times.
7. Place the samples back into the machine hit proceed and hit proceed again to
move to step# 3. When RT is complete, add 80uL of Nuclease free water to
samples and store in -20˚C freezer.
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Appendix 9: Designing Primers for PCR
1. Go to www.pubmed.com. Ensure that you search “nucleotide” and then type in
your gene of interest. Include the species
2. Find your gene of interest and click on FASTA. This will present you with your
gene of interest’s sequence. Copy only CDS or CODING REGION of the
sequence. If you do not use this your primers will not bind the correct sequence.
3. Blast this sequence using the link entitled “ RUN BLAST” along the upper right
of the webpage. This will compare your gene sequence to other sequences to
ensure that you will be amplifying the right gene.
4. Once the blast has been run, check the results to ensure that there are no matches
for other genes in the species that you will be working with.
5. Go to: http://frodo.wi.mit.edu/primer3/. Paste your sequence of interest in the
large box. This program will construct your primers for you .Change the product
size range. Usually you want your product to be between 80-300bp in size. Click
“Pick Primers”

6. Once you have the primers return to BLAST on the pubmed website and run a
BLAST on these primers to ensure that they will amplify only the gene you want
to look at in your species.
7. Go to: http://genome.ucsc.edu/. Click on the tab entitled PCR located at the top of
the webpage. Change the Genome tab to match the species you are working in.
Enter your Forward and Reverse primer as determined by Primer3 (you can copy
and paste it)
8. Observe the temperatures at which these primers anneal. If they are close together
for both the forward and reverse primer then you are all set

9. Order your primers through Integrated DNA Technologies (IDT) at the following
website: http://www.idtdna.com/Home/Home.aspx

*Dilute and optimize your primers once you receive them by running both PCR
and RT-PCR with an efficiency curve.
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Appendix 10: Polymerase Chain Reaction
1. Thaw reagents on ice (Promega Green Master mix, Tbx2 114 forward and reverse
primer working aliquots, cDNA sample)
2. Add 5uL of the cDNA to 8 tube strips once the master mix is added there will be a
total volume of 25µL
3. Make Master mix of 20uL for one reaction
Nuclease free water 5.5µL
Green master mix
12.5µL
Forward Primer
1.0µL
Reverse Primer
1.0µL
NOTE: This is for one sample, multiply it by the number of samples plus two for
pipetting errors. Be sure to include a negative and positive control. Transfer 20uL
of the master mix to 8 tube strips

4. Place the tubes into PCR machine and run the following program:
94˚C for 3min
94˚C for 30s
60˚C for 1min

X 40cycles

72˚C for1min
72˚C for 5min
10˚C forever
5. Once the PCR is complete ( about 21/2 hr), it is stored at 4˚C.
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Appendix 11: Real time PCR
1. Thaw the Reagents on ice.(Syber green wrapped in foil, forward and reverse
primers, cDNA)
2. Add 5uL of cDNA (diluted 1:5, 20uL of cDNA + 80uL of Nfree water) to the
tubes. Make sure to pipette to the bottom of the tube.
3. Make Master Mix. Amount will vary depending on the number of samples and
number of genes. Turn off lights when using the syber green as it is light
sensitive. Always add plus two for pippeting error and include negative and
positive controls.
Master Mix
2X Syber Green
Forward Primer
Reverse primer
NFree water

10uL
1uL
1uL
3uL

4. Add 15uL of master mix to each well in 96 PCR optical plate. Gently pipette
contents of well with master mix to facilitate mixing. Avoid forming bubbles as
this can result in incorrect values.
5. Seal it with a PCR adhesive film tightly to prevent evaporation and centrifuge the
plate at 1000RPM for 1-2minutes
6. Run plate in the ABI 7900 HT Fast real time machine using the following
protocol:
Stage 1: 50 °C for 2 min
95°C for 10 min
Stage 2: 95°C for 15 sec
60°C for 1 min
*Repeat for 40 cycles
Stage 3: 95°C for 15 s
60 °C for 15 s
95 °C with a 2% ramp for 2 min
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